SN | Title of the project | Objectives | Investigators | Budget | Funding Agency | Duration of Project |
1. | Development of diagnostics for porcine reproductive problems and selection of suitable vaccine candidate(s) | 1. Development of diagnostics for detection of viruses associated with porcine reproductive problems by conventional and molecular diagnostic techniques.
2. Isolation of the prevalent pathogens causing porcine reproductive problems in the Punjab region and their molecular epidemiology to develop effective disease control strategies.
3. Development of a virus repository to identify suitable candidate(s) for future vaccine development program.
4. Estimation of economic losses to the pig farmers due to infectious diseases. | PI: Dr. YPS Malik Co-PIs: Dr. Adarsh Mishra Dr. Deepali Kalambhe Dr. Manu M.
| Rs. 50 Lakhs | RKVY, GoI | 2022- 2024 |
2. | Modeling of indigenous diagnostics and immuno-potent vaccine candidates to combat African Swine Fever in India | 1. Dual gene targeted real-time qPCR methods for detection and confirmation of ASFV 2. Development of protein-based diagnostics for detection of ASF at field and laboratory condition | CC PI: Dr. YPS Malik CC Co-PI: Dr. BV Sunil Kumar Dr. Niraj Kumar Singh Dr. Ratan K Choudhary | Rs. 39.56 Lakhs | DBT, GoI | 2021- 2023 |
3. | Evaluation of tumour specific gene constructs for therapy of canine mammary tumours | i. Assessment of the safety of the vaccine construct(s) generated in phase I of the project in mice. ii. Generation of bi-cistronic recombinant plasmids (eukaryotic expression vectors) expressing murine mucin-I along with canine IL-2. iii. To evaluate safety and protective efficacy of therapeutic xenogenic DNA vaccine in clinical cases of canine mammary tumors. | PI: Dr. B.V. Sunil Kumar Co-PI: Dr. Kuldip Gupta Dr. Ashwani Kumar | Rs. 47.962 | Shortlisted in 2022 | - |
SN |
Title
of the project |
Objectives |
Investigators |
Budget
|
Funding
agency |
Duration
of Project |
1. |
Molecular characterization of
Canine Distemper virus field isolates For selection of suitable vaccine
candidate(S) |
1. Detection/Identification and
isolation of CDV from clinical samples by conventional and molecular
diagnostic techniques. 2. Molecular characterization of
CDV field isolates by cloning and sequencing of the important viral genes or
whole genome sequencing. 3. Cross neutralization assay to
find out the potential local vaccine candidate(s) (field CDV strains) as well
as to evaluate the existing CDV vaccines. |
PI: Dr. YPS Malik Co-PIs: Dr. Ramneek Dr. S.K. Uppal Dr. C.S. Mukhopadhyay Dr. Neetu Saini, |
Rs.
28.97 lakhs |
DBT, GoI |
2018- 2021 |
2.
|
Development
and Evaluation of Therapeutic Xenogenic DNA Vaccines Based on Canine
Homologous Marker Sequences against Mammary Tumors in Mice Models. |
1. Heterologous expression of
canine mammary tumor specific/ associated markers in prokaryotic /eukaryotic
system. 2. Generation of bi-cistronic
recombinant plasmids (eukaryotic expression vectors) expressing these genes
along with IL-2. 3. Evaluation of efficacy of these
therapeutic xenogenic DNA vaccines against induced mammary tumors in mice
models. |
PI:
Dr. B.V. Sunil Kumar Co-PIs: Dr.
Ramneek Dr.
J.S. Arora Dr.
Kuldip Gupta Dr.
Ashwani Kumar |
Rs. 31.4 lakhs |
DBT, GoI |
2018- 2021 |
3.
|
Establishment
of a laboratory for diagnosis of leptospirosis |
1. Development of a laboratory
committed for diagnosis of leptospirosis. 2. To ascertain the current status
of leptospirosis in northern India. |
PI:
Dr. Satparkash Singh Co-PIs: Dr.
Simranpreet Kaur Dr.
Randhir Singh Dr.
ST Singh Dr.
Dipak Deka Dr.
A.K. Arora |
Rs.
48.432 lakhs |
DBT,
GoI |
2018- 2021 |
4.
|
Development
of user-friendly diagnostic kit for Marek’s disease |
1. Development and evaluation of
recombinant gE protein based indirect ELISA for detection of antibodies
against MDV infection |
PI:
Dr. Niraj Kumar Singh Co-PIs: NA |
Rs.
6.91 Lakhs |
UGC,
GoI |
2014- 2018 |
5.
|
Development
of sub-viral particles of Infectious Bursal Disease virus as a potential
vaccine and diagnostic candidate |
1. To construct recombinant
baculovirus having VPX and/or VP2 of Infectious Bursal Disease Virus (IBDV) 2. To generate subviral particles
of IBDV in insect cell line (Sf-9) |
PI:
Dr. Niraj Kumar Singh Co-PIs: Dr.
Dipak Deka Dr.
Ramneek |
Rs.
26.35 Lakhs |
DBT,
GoI |
2014- 2018 |
6.
|
Development
of subviral particle of Japanese encephalitis virus (JEV) as a candidate
vaccine against JEV |
1. To generate subviral particles
of IBDV in insect cell line (Sf-9) 2. To generate subviral particles
of JEV in insect cell line (Sf-9) 3. To evaluate the subviral
particles as a vaccine candidate |
PI:
Dr. Niraj Kumar Singh Co-PIs: Dr.
Dipak Deka |
Rs.
16.4 Lakhs |
DAE,
GoI |
2014- 2018 |
7.
|
Studies
on Cloning and Expression of Heat Shock Proteins (Hsps) of Brucella spp. and
their Immunological Characterization in Experimental animals |
1. Cloning and heterologous
expression of Heat Shock Protein (dnaK and dnaJ) genes of Brucella spp. 2. Immunological characterization
of the expressed proteins in experimental animal model. |
PI:
Dr. B.V. Sunil Kumar Co-PIs:
NA |
14.158
Lakh |
UGC,
GoI |
2014- 2017 |
8.
|
Development
and Evaluation of Sero-diagnostic Assay for Timely Diagnosis and Prognosis of
Mammary Tumors |
1. To study expression profile of
Mammaglobin, HSP90 and ErbB genes in normal and mammary tumor cases by qPCR
(with dog as model animal). 2. To clone and express candidate
biomarkers (mammaglobin, HSP90 and ErbB) in heterologous expression system. 3. To develop hyperimmune antisera
against the expressed proteins in suitable laboratory animals and to develop
sandwich ELISA for diagnosis and prognosis of mammary tumors. |
PI:
Dr. B.V. Sunil Kumar Co-PIs: Dr.
Ravikant Agrawal Dr.
Dipak Deka |
19.90
Lakh. |
DBT,
India |
2013- 2017 |
9.
|
Development
of virus-like particle (VLP) of Japanese encephalitis virus as a potential
vaccine candidate |
1. To construct recombinant
lentiviral vector having pre-membrane (prM) and envelope (E) genes of
Japanese encephalitis virus (JEV) 2. To generate permanently
transduced BHK-21 cell line for constitutive expression of VLP 3. To evaluate the VLP as a
vaccine candidate |
PI:
Dr. Niraj Kumar Singh Co-PIs: Dr.
Dipak Deka Dr.
Ramneek Dr.
PK Gupta |
38.276
Lakh |
DBT,
India |
2013- 2017
|